JP2009535370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535370A5 JP2009535370A5 JP2009508198A JP2009508198A JP2009535370A5 JP 2009535370 A5 JP2009535370 A5 JP 2009535370A5 JP 2009508198 A JP2009508198 A JP 2009508198A JP 2009508198 A JP2009508198 A JP 2009508198A JP 2009535370 A5 JP2009535370 A5 JP 2009535370A5
- Authority
- JP
- Japan
- Prior art keywords
- dystonia
- dyskinesia
- induced
- paroxysmal
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000010118 dystonia Diseases 0.000 claims 14
- 208000014094 Dystonic disease Diseases 0.000 claims 13
- 208000012661 Dyskinesia Diseases 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 5
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000001314 paroxysmal effect Effects 0.000 claims 3
- 229960003312 retigabine Drugs 0.000 claims 3
- 206010008748 Chorea Diseases 0.000 claims 2
- 208000012075 Paroxysmal dystonia Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 208000012601 choreatic disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 239000004036 potassium channel stimulating agent Substances 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021718 Induced labour Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000009985 drug-induced dyskinesia Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 230000000701 neuroleptic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06009064 | 2006-05-02 | ||
| PCT/EP2007/003830 WO2007128462A1 (en) | 2006-05-02 | 2007-04-30 | Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535370A JP2009535370A (ja) | 2009-10-01 |
| JP2009535370A5 true JP2009535370A5 (https=) | 2010-05-06 |
Family
ID=38227827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009508198A Withdrawn JP2009535370A (ja) | 2006-05-02 | 2007-04-30 | ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090318507A2 (https=) |
| EP (1) | EP2012769A1 (https=) |
| JP (1) | JP2009535370A (https=) |
| CA (1) | CA2650853A1 (https=) |
| WO (1) | WO2007128462A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070065463A1 (en) | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
| AR070513A1 (es) * | 2007-08-01 | 2010-04-14 | Lundbeck & Co As H | Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor |
| JP2011526889A (ja) * | 2008-06-30 | 2011-10-20 | アフギン ファーマ，エルエルシー | 局所局部的神経作用療法 |
| JP2013517315A (ja) * | 2010-01-20 | 2013-05-16 | グラクソ グループ リミテッド | 新規組成物 |
| HK1244715A1 (zh) | 2015-03-02 | 2018-08-17 | 阿福金制药有限责任公司 | 用大麻素的局部区域神经影响性疗法 |
| US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
| CA3026149A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
| CN110225754A (zh) * | 2016-11-22 | 2019-09-10 | 奥维德医疗公司 | 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法 |
| SI3571193T1 (sl) | 2017-01-23 | 2022-04-29 | Cadent Therapeutics, Inc. | Modulatorji kalijevega kanalčka |
| DE102017007385A1 (de) | 2017-08-02 | 2019-02-07 | Christoph Hoock | Maleatfreie feste Arzneimittelformen |
| WO2019217924A1 (en) | 2018-05-11 | 2019-11-14 | Xenon Pharmaceuticals Inc. | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
| CA3116339A1 (en) | 2018-10-22 | 2020-04-30 | Cadent Therapeutics, Inc. | Crystalline forms of potassium channel modulators |
| TWI886158B (zh) | 2019-10-10 | 2025-06-11 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| MX2022005490A (es) | 2019-11-08 | 2022-08-10 | Xenon Pharmaceuticals Inc | Metodos para el tratamiento de trastornos depresivos. |
| CA3159876A1 (en) * | 2019-12-06 | 2021-06-10 | James MURROUGH | Method of treatment with kcnq channel openers |
| US11957675B2 (en) | 2021-02-09 | 2024-04-16 | Xenon Pharmaceuticals Inc. | Methods and uses for treating anhedonia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN172468B (https=) * | 1990-07-14 | 1993-08-14 | Asta Medica Ag | |
| GB9915414D0 (en) * | 1999-07-01 | 1999-09-01 | Glaxo Group Ltd | Medical use |
| US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| WO2006055927A2 (en) * | 2004-11-17 | 2006-05-26 | The Cleveland Clinic Foundation | Pathogenic gene and protein associated with paroxysmal dyskinesia and epilepsy |
| EP2623099A1 (en) * | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
-
2007
- 2007-04-30 WO PCT/EP2007/003830 patent/WO2007128462A1/en not_active Ceased
- 2007-04-30 EP EP07724757A patent/EP2012769A1/en not_active Withdrawn
- 2007-04-30 JP JP2009508198A patent/JP2009535370A/ja not_active Withdrawn
- 2007-04-30 US US12/296,960 patent/US20090318507A2/en not_active Abandoned
- 2007-04-30 CA CA002650853A patent/CA2650853A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535370A5 (https=) | ||
| JP2007529532A5 (https=) | ||
| CY1112499T1 (el) | Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων | |
| EP2011487A3 (en) | Pharmaceutical compositions for gastroinetestinal drug delivery | |
| JP2007500154A5 (https=) | ||
| JP2009538276A5 (https=) | ||
| JP2012517449A5 (https=) | ||
| JP2006508953A5 (https=) | ||
| IN2009KN03959A (https=) | ||
| NO20073403L (no) | Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1 | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| NZ602029A (en) | Use of meloxicam for the long-term treatment of kidney disorders in cats | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| WO2008092072A3 (en) | Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof | |
| MX2009005798A (es) | Recuperacion de apoplejia. | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| EP1781277A4 (en) | COMBINATION PREPARATION | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| MX2009004579A (es) | Composicion farmaceutica que tiene actividad antisicotica, antidepresiva o antiepileptica, con efecto colateral reducido. | |
| WO2007057221A3 (en) | Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases | |
| TW200637544A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| EP1750703A4 (en) | METHOD FOR REDUCING GASTROINTESTINAL TOXICITY BY ADMINISTRATION OF TEGAFUR | |
| JP2008516909A5 (https=) | ||
| JP2005511708A5 (https=) |